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The prognosis for patients with acute 
myeloid leukemia (AML) is currently 
still rather poor, mainly due to disease 
relapse. Whereas current standard 
chemotherapy strategies lead to an 
initial reduction of leukemic blasts in 
the majority of patients, a small cell 
population persists and is apparently not 
efficiently targeted, leading to recurrence 
of the disease with variable latency. In 
order to improve the effectiveness of 
AML therapy, further characterization 
of those disease-initiating cells is 
warranted, which is the scope of this 
thesis.
In AML, various mutations and genetic 
alterations are found in the leukemic 
cells and lead to the characteristic 
clinical picture of the disease, which is 
defined by an accumulation of leukemic 
blasts in the bone marrow and peripheral 
blood. Despite the genetic heterogeneity, 
AMLs commonly follow a particular 
pattern of disease evolution which is 
characterized by a stepwise acquisition 
of mutations. Early events in AML 
evolution occur in normal hematopoietic 
stem and progenitor cells (HSPCs) 
leading to the formation of preleukemic 
HSPCs, which still have the capacity 
to differentiate normally, however, 
have altered properties regarding self-
renewal and maintenance. Later events 
in those cells cause differentiation- and 
proliferation abnormalities resulting 
in the formation of leukemia stem cells 
(LSCs), which eventually give rise to 
full-blown leukemia. In contrast to the 
majority of leukemic cells, LSCs have 
self-renewal properties and are capable 
of initiating and maintaining the disease. 
Importantly, LSCs are thought to be 
chemoresistant and to drive disease 
relapse. Thus, studying the molecular 
mechanisms that underlie those LSC-
specific properties might help to identify 
novel targets for AML therapy. 
The transcriptional co-regulator CITED2 
has important roles in promoting self-
renewal and maintenance of both 
HSCs and LSCs. It was previously 
shown that knockdown of CITED2 in 
AML cells interferes with their long-
term expansion, however, molecular 
mechanisms behind this observation 
remained unclear. In chapter 2, we 
aimed to study the in vivo role of CITED2 
in AML maintenance and to investigate 
downstream alterations in signaling 
pathways upon CITED2 reduction. For 
that purpose, AML cells were transduced 
with a lentiviral construct for RNAi-
mediated knockdown of CITED2. We 
observed that mice transplanted with 
CITED2-knockdown AML cells had a 
significant longer survival compared 
to mice transplanted with control AML 
cells, confirming a crucial role of CITED2 
in disease maintenance. In vitro studies 
revealed that reduction of CITED2 leads 
to increased p53-mediated apoptosis, 
most likely resulting from an inhibition 
of the AKT signaling pathway. Reduction 
of CITED2 led to decreased levels 
of phosphorylated AKT, increased 
expression of the AKT-pathway inhibitor 
PHLDA3, as well as to a decreased 
expression of the AKT-activator SOX4 
and the AKT-downstream target BCL2. 
The apoptotic phenotype of CITED2-
knockdown cells could be rescued by 
simulations downregulation of PHLDA3 
or upregulation of BCL2. We further 
observed that reduction of CITED2 led 
to a decreased interaction of p53 with its 
inhibitor MDM2, resulting in increased 
amounts of total p53 protein. Together 
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Increased replating capacity of PU.1KD/
KD/CITED2 cells in in vitro assays 
eventually resulted in outgrowth of 
transformed cells, while upregulation of 
CITED2 in PU.1KD/KD cells enhanced their 
engraftment in in vivo transplantation 
studies, however, without signs of 
leukemic transformation. Altered self-
renewal and maintenance of HSPCs 
without a block in differentiation has 
been described as an early event in 
AML evolution, suggesting that the 
combined PU.1/CITED2 deregulation 
programs a preleukemic state. This was 
supported by gene expression studies 
showing that transcriptional changes 
induced by combined PU.1/CITED2 
deregulation are also found in patient 
AML cells compared to normal CD34+ 
cells. In summary, our findings from 
chapter 3 suggest that simultaneous 
downregulation of PU.1 and upregulation 
of CITED2 has a synergistic effect on 
self-renewal pathways that are linked to 
clonal hematopoiesis, which is known to 
precede leukemic transformation.
Loss of stemness potential in Cited2-
deleted murine HSCs was previously 
shown to be accompanied by signs of 
increased mitochondrial activity such 
as elevated mitochondrial membrane 
potential, elongation of mitochondrial 
shape and elevated ROS production.1 In 
the second part of this thesis, we focused 
on investigating metabolic properties 
of AML-initiating cells. Recent studies 
highlighted that LSCs characteristically 
have low levels of reactive oxygen species 
(ROS), which result from a combination 
of low mitochondrial activity and high 
activity of ROS-removing pathways 
such as autophagy. In chapter 4, ROS-
regulating pathways and their relevance 
for the functionality of both normal- and 
leukemic stem cells were described in 
the data from chapter 2 indicate that 
CITED2 translates its important role in 
AML maintenance in part by regulating 
genes- and pathways that interfere with 
p53 activation. 
The transcription factor PU.1 is a 
key regulator of hematopoiesis and 
has important functions for both 
maintaining HSPCs and differentiation 
of the myeloid linage. Even though 
mutations of PU.1 itself are rarely 
found in AML, its expression or 
activation is frequently disturbed by 
AML-associated alterations. PU.1-
knockdown mice, which resemble such 
a condition of impaired PU.1 activity, 
develop AML after a pre-leukemic 
phase of several months, indicating 
that additional alterations are required 
for the formation of disease-initiating 
cells. Potential candidates that facilitate 
transformation of preleukemic PU.1-
knockdown cells might be factors that 
increase their maintenance or accelerate 
their proliferation properties. It was 
recently shown that CITED2, which has 
crucial roles in stem cell maintenance, 
is negatively regulated by PU.1, 
suggesting that both factors act in the 
in same signaling network. In chapter 
3, we aimed to investigate a potential 
synergistic effect of simultaneous 
PU.1 downregulation and CITED2 
upregulation on stem cell biology and 
AML pathogenesis. Using lentiviral 
constructs for either overexpression of 
CITED2 or RNAi-mediated knockdown 
of PU.1, we found that simultaneous 
PU.1/CITED2 deregulation in human 
CD34+ cord blood (CB) cells, as well as 
CITED2 upregulation in preleukemic 
murine PU.1-knockdown (PU.1KD/
KD) bone marrow cells, significantly 
increased the maintenance of HSPCs 
compared to either factor alone. 
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activity and showed a significantly lower 
number and activity of mitochondria. 
By performing RNA-seq studies we 
could identify gene signatures that are 
shared among ROS-low or ROS-high 
CD34+ AML cells across patients with 
various genetic backgrounds. Genes 
upregulated in ROS-low cells were 
associated with negative regulation of 
signaling pathways (SPRY1, DUSP10, 
PIK3IP1, DDIT4) and were enriched 
for stemness-associated genes (ABCB1, 
MEIS1, CD109, GFI1B). Downregulated 
genes in ROS-low cells were related to 
increased cell differentiation. Functional 
validation of the drug efflux transporter 
ABCB1 demonstrated that ROS-low 
cells have strikingly higher ABCB1 
activity compared to ROS-high cells, 
which was previously associated with 
poor prognosis in AML. Functional 
analysis demonstrated that CD34+ 
AML cells with low ROS levels have 
an increased sensitivity to the BCL2 
inhibitor Venetoclax despite the fact 
that we observed comparable levels of 
BCL2 expression in ROS-low and ROS-
high cells. These findings suggest that 
the low mitochondrial activity in ROS-
low cells makes them more vulnerable 
to inhibition of important mitochondrial 
regulators. In summary, our data from 
chapter 5 highlights that CD34+ AML 
cells with low ROS levels have stemness-
related features, and thereby most likely 
coincide with the LSC population, which 
can be efficiently targeted by BCL2 
inhibition. 
detail. This included HIF-1α -, AMPK 
-, mTOR-, FOXO- and SIRT- signaling, 
as well as of crucial players in DNA 
damage response pathways such as 
ATM. Moreover, it was highlighted that 
the metabolic state of LSCs implicates 
certain vulnerabilities of these cells. 
LSCs are highly depended on their 
remaining levels of mitochondrial 
activity, and thereby rely on pathways 
that regulate mitochondrial integrity. 
The anti-apoptotic protein BCL2 has 
an important role in maintaining the 
mitochondrial membrane potential 
under stress conditions and was shown 
to promote LSC maintenance. Similar, 
proteins involved in mitophagy such 
as FIS1 have been found to be critical 
for LSC survival, and thereby serve as 
promising new targets for AML therapy. 
Even though previous studies 
demonstrated that LSCs have lower 
ROS levels compared to the total AML 
cell population, it remained unclear if 
ROS levels within the stem cell enriched 
CD34+ AML subtraction are indicative 
for stemness properties. In chapter 5, 
we investigated in detail how ROS levels 
within the CD34+ AML cell population 
correlate with cellular functions and 
characteristics such as morphology, 
metabolic activity, gene expression and 
drug responsiveness. In our study, we 
compared features of CD34+ AML cells 
that were sorted into ROS-low and 
ROS-high cell populations, which were 
defined as the cell fractions with the 
15% lowest and highest signal intensity 
for a fluorescence-based ROS dye. 
We observed that ROS-low cells were 
remarkably smaller compared to ROS-
high cells, with a prominent nucleus 
and scarce cytoplasm, and enriched for 
CD34+/CD38- cells. Furthermore, ROS-
low cells had a decreased metabolic 
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critical for AML cell survival. 
TP53 mutations are present in less than 
10% of de novo AMLs, but are observed 
with a frequency of ~30% in therapy 
related AMLs (t-AMLs)13 and with a 
frequency of ~70% in complex karyotype 
AMLs.14 The majority (70-80%) of TP53 
mutations are missense mutations  in 
„hot-spot“ codons resulting in amino 
acid changes and consequently altered 
protein structure, folding and stability. 
These mutations are not only associated 
with loss of p53 tumor suppressive 
function (LOF), but also acquire gain of 
function (GOF) properties that promote 
tumor aggressiveness and correlate 
with poor prognosis.15,16 Other types of 
TP53 mutations include genomic loss 
of TP53, as it is observed in patients 
with deletions of 17p.17 Notably, patients 
with germline mutations in the TP53 
gene only rarely develop AML, but are 
rather associated with different types of 
solid tumors. Also, TP53 mutations are 
more common in t-AMLs than de novo 
AMLs, which suggests that inactivated 
or altered p53 function is not sufficient 
for leukemic transformation, but instead 
results in increased cellular stress 
resistance. In combination with other 
alterations or stressors such as cytotoxic 
therapy, this increased resistance likely 
promotes leukemogenesis. In our study, 
we observed that knockdown of CITED2 
results in increased stabilization of p53. 
We therefore hypothesize that increased 
CITED2 expression observed in AML 
has the opposite effect. High CITED2 
levels might interfere with p53 activation 
and confer, in certain way similar to 
TP53 mutations or to non-mutational 
alteration in the p53 regulatory network, 




Interference with p53 inactivation 
as a therapeutic strategy in AML
The data described in chapter 2 
demonstrate that reduction of CITED2 
levels in AML cells results in an increased 
amount of p53 protein and increased 
levels of p53-mediated apoptosis. 
Reactivation of p53 function is a 
particular important strategy for AML 
therapy. Approximately 90% of de novo 
AML cases do not present with mutations 
in the TP53 gene, but often with p53 
inactivation due to dysfunctions in the 
p53 regulatory network.2 TP53, located 
on the short arm of chromosome 17, 
regulates a multitude of genes involved 
in apoptosis, DNA, repair, growth 
arrest and cell differentiation, and 
thereby represents an important tumor 
suppressor.3 Despite the presence of the 
p53 wild type protein, p53 functions can 
be impaired due to abnormalities in p53-
regulator proteins. P53 is bound and 
inactivated by its endogenous inhibitors 
mouse double minute 4 homolog (MDM4 
or MDMX)4 or the mouse double minute 
2 homolog (MDM2),5 which are both 
often overexpressed in p53 wild type 
AMLs.6–10 Pharmacological disruption of 
these interactions serves as a promising 
strategy to restore p53-mediated tumor 
suppressor functions. Molecules for 
p53-reactivation via MDM2 or MDMX 
inhibition are currently investigated 
in early phase clinical trials.11,12 Our 
study described in chapter 2 suggests 
that reduction of CITED2 levels results 
in decreased formation of p53-MDM2 
complexes, indicating that CITED2 
is part of the p53 regulating network 
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a significantly higher contribution of 
human cells to hematopoiesis than 
mice that received control cells, without 
affecting differentiation.23 Even though 
CITED2-mediated effects on increased 
engraftment could also have other 
reasons, such as altered cell quiescence, 
high CITED2 levels might protect 
primitive cells – similar to p53 alterations 
- from stress-induced apoptosis. This 
notion is supported by the finding that 
CITED2-high CD34+CD38- cells have a 
lower amount of AnnexinV-positive cells 
than control cells.23
Apparently, both HSCs with impaired p53 
functions and HSCs with high CITED2 
expression gain a survival advantage 
over other HSCs, but are still capable of 
normal differentiation – a condition that 
can lead to clonal hematopoiesis (CH). 
CH is defined as a state where a single 
mutant HSC contributes to a significant 
clonal proportion of mature blood 
lineages.24 In the multistep-process of 
AML development, CH often precedes 
malignant transformation,25,26 however, 
it is also observed in healthy individuals. 
CH is related to age and observed in 10% 
of people over the age of 65 and 20% of 
people older than 90 years.26 Somatic 
mutations detected in CH overlap with 
mutations recurrently found in AML 
and often include the genetic modifiers 
DNMT3A, TET2 and ASXL1. If CH is 
observed in combination with leukemia-
associated mutations, but signs of 
cytopenia or malignant transformation 
are absent, the condition is referred to as 
clonal hematopoiesis of indeterminate 
potential (CHIP).27 Originally, CHIP was 
defined as the presence of clonal blood 
cell populations harboring leukemic 
driver mutations with an variant allele 
frequency (VAF) of ≥2%,27 but recent 
studies indicated that also a lower VAF 
The role of p53 and potentially of 
CITED2-mediated p53 regulation 
in clonal HSC expansion
P53 was shown to have crucial roles in 
regulating HSCs in both steady-state 
and stress conditions. During steady 
state hematopoiesis, p53 regulates 
the balance between HSC quiescence 
and self-renewal. In vivo studies 
demonstrated that absence of p53 
promotes self-renewal, since Tp53-
null mice where shown to have a two- 
to threefold increase of cells capable 
of long-term blood reconstitution.18,19 
In stress conditions, p53 induces 
expression of genes that protect the 
genetic integrity of cells, including genes 
involved in growth arrest, DNA repair 
and apoptosis.20 Recently, Chen et al 
showed that mice with a heterozygous 
expression of the p53 mutant p53R248W 
don’t have an increased number of long-
term HSCs, but that mutant HSCs have 
a significantly increased repopulation 
capacity compared to wild-type HSCs, 
as demonstrated by competitive bone 
marrow transplantation assays.21 This 
likely reflects an increased resistance 
of p53 mutant cells to transplantation 
induced stress. Notably, both 
p53R248W/+ and p53-/- mice did not 
show an impaired differentiation of 
the myeloid or lymphoid lineage,21,22 
indicating that absent or altered p53 
function in HSCs does not cause 
leukemic transformation, but rather 
results in outgrowth of those cells over 
time due to altered self-renewal and 
survival linked to an increased stress 
resistance. Interestingly, a similar 
phenotype was previously observed in 
mice transplanted with human CD34+ 
cord blood cells overexpressing CITED2. 
In this study, mice that received 
CITED2-high cord blood cells showed 
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partly explained by the role of AKT in 
the repair of (therapy-induced) DNA 
damage.43 Increased AKT activation likely 
promotes leukemic cell survival during 
chemotherapy by enhancing the DNA 
repair capacity. LSCs were shown to have 
lower levels of activated AKT compared 
to more differentiated blasts,44 however, 
the remaining levels of AKT still seem to 
contribute to their oncogenic properties, 
as Quotti Tubi et al. demonstrated that 
targeting AKT signaling can sensitize 
LSCs for chemotherapeutic treatment.45 
Inhibition of AKT signaling alone 
appears to be not sufficient for effective 
AML treatment, since clinical trials with 
inhibitors for AKT, PI3K and MTOR 
mostly failed.33 However, inhibition 
of AKT likely is beneficial as part of 
combination treatments. Alternatively, 
targeting of molecules that affect multiple 
pathways relevant in AML – such as 
CITED2 – could represent interesting 
therapy approaches. This thesis further 
describes that knockdown of CITED2 
in leukemic cells results in reduced 
expression of the anti-apoptotic protein 
and mitochondrial regulator BCL2. 
The apoptotic phenotype of CITED2-
knockdown cells could be completely 
rescued by simultaneous upregulation of 
BCL2, indicating that a CITED2/BCL2-
axis may play an important role for AML 
cell survival. As described in detail in 
chapter 4, BCL2 function is crucial for 
the maintenance of LSCs, mainly due 
to its role on regulating OXPHOS.46 
Moreover, overexpression of BCL2 
is associated with chemotherapeutic 
resistance and corresponds with poor 
overall survival.47,48 
In summary these data highlight 
that targeting CITED2 functions 
simultaneously hits multiple pathways 
that have a crucial role for AML cell 
cutoff is associated with an increased risk 
for developing AML.28 Presence of more 
than one leukemia-associated mutation 
and a bigger clone size (VAF>10% for 
DNMT3A and TET2 mutations) increase 
the chance to progress to AML, and both 
of these parameters correlate with age.29 
Among the top five genes that are 
recurrently found mutated in individuals 
with CHIP is Tp53,25,26,30,31 highlighting 
the role of dysfunctional p53 in conferring 
a competitive advantage to HSCs. Thus, 
p53 mutations represent an initiating 
event that primes HSCs for malignant 
transformation, however, acquisition 
of additional alterations for leukemia 
onset is required. Likely, also factors that 
regulate p53 abundancy and activity, 
including CITED2, play a role in clonal 
expansion of HSCs, thereby increasing 
the risk for leukemic transformation.
Targeting CITED2- prospects and 
limitations
Besides the role of CITED2 as a p53 
regulator, this thesis further describes 
the impact of CITED2 on AKT-signaling 
and BCL2 expression. As shown in 
chapter 2, downregulation of CITED2 
in leukemic cells resulted in decreased 
levels of phosphorylated (and thus 
activated) AKT and decreased expression 
of BCL2. This observation highlights that 
CITED2 has a central role in a network 
of three signaling pathways frequently 
deregulated in AML and associated with 
poor prognosis and therapy resistance. 
Constitutive activation of AKT signaling 
is found in 50-70% of AML patients32 
and has an important role for the 
initiation, proliferation and maintenance 
of leukemic cells.33–38 Furthermore, 
activation of AKT is associated with 
chemoresistance,39–42 which is at least 
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SMAD3 was associated with an adverse 
prognosis in AML patients undergoing 
chemotherapy, and the SMAD3 
interaction partner SOX4 was shown 
to be involved in regulating LSC self-
renewal.51,52 Furthermore, HSCs and 
LSCs might have an altered dependency 
on CITED2-mediated regulation of 
CBP/p300 targets. Shedding light on 
these questions might help to identify a 
therapeutic window of CITED2-based 
targeting. 
Potential roles of the PU.1/CITED2 
axis in preleukemic stages
Development of AML is a multistep-
process that requires acquisition of 
multiple genetic alterations.53,54 The phase 
preceding malignant transformation, in 
which leukemia-associated mutations 
are already present but don’t cause a 
block in differentiation, is referred to 
as preleukemic phase or preleukemia. 
In general, CHIP and preleukemia have 
similar characteristics such as presence 
of mutations recurrently found in 
leukemia and alterations in self-renewal, 
proliferation and stress-resistance of 
HSCs.55 However, in contrast to CHIP, 
the term “preleukemia” is usually 
used if a certain condition definitively 
results in progression to malignant 
transformation. For instance, in human 
studies, the name “preleukemic phase” 
is often used to retrospectively describe 
genetic- or functional alterations of 
HSCs that were identified prior to AML 
diagnosis, or in cases where certain 
mutations – such as germline mutations 
in CEBPA – result in a nearly complete 
penetrance for development of AML.56 
In addition, mouse models that develop 
AML with high frequency, but only after 
a certain period of time, are described 
to undergo a preleukemic phase. This 
survival and maintenance. A recent study 
demonstrated that the p53 apoptotic 
network contributes to resistance of 
leukemic cells to the BCL2 inhibitor 
Venetoclax,49 and thus targeting both 
BCL2 and p53 simultaneously might 
eliminate more effective LSCs. However, 
the downside of targeting CITED2 is 
that this protein is also essential for the 
survival of normal HSCs. Our group 
previously showed that knockdown of 
CITED2 in human CD34+ cord blood 
cells significantly impairs their colony 
forming ability.23 Additionally, murine 
gene knockout studies showed that 
deletion of CITED2 in HSCs results in 
multilineage bone marrow failure and 
that CITED2 is only dispensable for 
committed hematopoietic cells.50 In 
ideal circumstances, agents used for 
AML therapy should target LSCs and 
leukemic blasts, while sparing out the 
healthy compartment. However, also 
current chemotherapeutic treatment 
strategies are harmful to normal 
HSPCs, but apparently fail frequently 
to efficiently target the AML cells that 
drive disease relapse. Additionally, 
it would be interesting to study 
pharmacological CITED2 inhibition 
in leukemic cells, which likely has 
different effects compared to a complete 
gene knockdown as it was done in 
our study. CITED2 consists of several 
domains which enable the interaction 
of CITED2 with multiple other proteins. 
The detailed molecular mechanisms of 
CITED2 actions are still not elucidated 
and it remains to be investigated which 
interactions of CITED2 with other 
proteins are driving its pro-survival 
role for leukemic cells. For example, it 
would be interesting to investigate if 
interference with the CITED2-SMAD2/3 
interaction affects leukemic cell survival 
and maintenance. High expression of 
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additional hits.60 
Overexpression of the DNMT3A mutant 
R882H in murine HSPCs was shown 
to result in decreased expression of 
several differentiation-associated 
genes, including the gene encoding 
PU.1.61 Furthermore, PU.1 was shown 
to directly interact with DNMT3A for 
target gene repression,23,62 a process 
that seems to be altered in the presence 
of mutant DNMT3A. PU.1 was also 
shown to directly interact with TET2 for 
modulating target gene expression during 
monocyte-to-osteoclast differentiation.63 
Therefore, TET2 mutants potentially 
also effect PU.1 function during myeloid 
differentiation, however, experimental 
evidence for this hypothesis is still 
lacking. Another mutation that was 
clearly associated with reduction of 
PU.1 levels is AML1-ETO,64,65 which is 
one of the most frequent translocation 
products found in de novo AML.66 The 
AML1-ETO fusion protein, generated 
by the t(8;21)(q22;q22) rearrangement, 
can be detected in AML patients long 
before the moment of diagnosis.67–69 
Expression of AML1-ETO in human 
CD34+ HSPCs resulted in enhanced self-
renewal and dysregulated differentiation 
without leukemic transformation, 
and thus generation of a preleukemic 
condition.70 This is in line with studies 
showing that expression of AML1-
ETO alone in both murine and human 
HSPCs is not sufficient for leukemic 
transformation.66,71–74 At the time of AML 
diagnosis, AML1-ETO is frequently 
found together with other mutations 
that promote cell proliferation and 
confer oncogenic cooperativity such 
as CBL mutations,75 RAS mutations,76 
or activating c-KIT mutations.77 This 
strongly suggests that overexpression 
of CITED2 in PU.1KD/KD cells promotes 
includes PU.1-knockdown (PU.1KD/KD) 
mice, which show reduced expression 
of PU.1 and develop AML with a latency 
of approximately six months, with 
additional mutations present in the 
malignant cells.57
In order to investigate factors that might 
promote maintenance of preleukemic 
cells or potentially accelerate malignant 
transformation, we investigated the 
effects of CITED2 overexpression in 
preleukemic murine PU.1KD/KD cells 
(chapter 3 of this thesis). We observed 
an outgrowth of CITED2-PU.1KD/KD 
cells in in vitro assays and increased 
engraftment of CITED2-PU.1KD/KD HSPCs 
in transplantation assays compared 
to control-PU.1KD/KD HSPCs. This 
likely indicates that CITED2-PU.1KD/KD 
HSPCs have altered self-renewal and 
survival properties, which is in line 
with known functions of CITED2 in 
HSC maintenance and increased p53-
dependent stress resistance (see chapter 
2). However, whereas full deletion of 
Tp53 in PU.1KD/KD mice was previously 
shown to result in more aggressive 
AML,22 CITED2 overexpression in 
PU.1KD/KD  HSPCs was not sufficient for 
accelerated leukemic transformation. 
Lack of accelerated AML development 
in PU.1KD/KD cells and CITED2-PU.1KD/KD 
cells might coincide with the observation 
that mutations associated with impaired 
PU.1 expression or function are 
frequently observed in early phases of 
AML evolution, long before the event of 
malignant transformation. Mutations in 
the gene encoding PU.1 itself are rare,58,59 
but several mutations associated with 
premalignant stages (e.g. DNMT3A, 
TET2, AML1-ETO) are associated with 
(modest) reduction of PU.1 levels, which 
is known to be sufficient for promoting 
leukemogenesis in combination with 
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of ROS. We demonstrated that ROS-
low LSCs have a reduced mitochondrial 
content, low levels of ATP and a different 
gene expression signature that suggests 
an increased stemness potential of 
ROS-low LSCs compared to their ROS-
high counterparts, which is in line with 
in vivo studies.46 It is unlikely that this 
difference can be explained by differences 
in genetic background in view of the 
common molecular mutations in both 
fractions. Recently it was shown that 
phenotypic variability in cells with an 
identical genetic background is strongly 
dictated by the mitochondria content.80 
Differences in mitochondrial content 
and function were found to account for 
approximately half of the differences 
observed on protein level between cells. 
This observation is closely linked to the 
fact that eukaryotic gene expression is 
an energy demanding process and that 
the majority of cellular ATP is used 
for mRNA- and protein synthetisis.81 
A different number of mitochondria, 
which are the most potent ATP source in 
eukaryotic cells, was found to influence 
mRNA abundance, translation and 
alternative splicing.80 Global gene 
expression rates were suggested to be 
proportional to cell growth,82 and our 
observation that ROS-low LSCs are 
significantly smaller than ROS-high cells 
supports the notion that LSCs might 
have in general lower transcription- 
and translation rates compared to other 
leukemic cells. Sources of mitochondrial 
heterogeneity include asymmetric 
partitioning at cell division, cell cycle 
stage and mitochondrial dynamics,83 
which has been shown to be altered 
in LSCs.84 A study by de Almeida et al. 
suggested that HSCs have a relatively 
high mitochondrial mass, however, 
the activity of these mitochondria 
was shown to be low, which likely has 
maintenance of preleukemic cells, but 
that additional hits are required for 
leukemic transformation. Increased 
maintenance of CITED2-PU.1KD/KD cells 
potentially increases the risk for their 
malignant transformation, and it would 
be interesting to address this hypothesis 
in future studies.
Studying the biology of preleukemic HSCs 
is highly relevant, since LSCs emerge 
from these cells. According to the clonal 
evolution model of AML, interference 
with expanded preleukemic HSCs might 
prevent the formation of transformed 
LSCs. Furthermore, preleukemic HSCs 
might play a role in disease relapse. AML 
relapse can originate from a subclone 
that was already present at diagnosis,78,79 
or from preleukemic cells that often 
survive chemotherapy,55 and therefore 
represent an increased risk of disease 
recurrence - even if LSCs are successfully 
eliminated. 
A different mitochondrial content 
likely plays a major role for LSC-
specific features 
In addition to mediating resistance to 
p53-mediated apoptosis, the stemness 
protein CITED2 was also shown to be 
involved in mitochondrial regulation. 
Cited2 deletion in murine HSCs resulted 
in loss of their stemness potential, 
accompanied by signs of increased 
mitochondrial activity such as elevated 
mitochondrial membrane potential, 
elongation of mitochondrial shape and 
elevated ROS production.1 Chapter 4 
and 5 of thesis, as well as numerous 
previous studies, describe that LSCs have 
different metabolic properties compared 
to the non-LSC population of leukemic 
blasts, including a characteristically low 
mitochondrial activity and low levels 
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A low mitochondrial content and/or 
activity can influence gene expression 
not only by providing less energy for 
transcription and translation, but also 
by producing less ROS which serve as 
signaling molecules. Recently, Pollyea et 
al demonstrated that standard induction 
chemotherapy results in elevation of 
ROS, but does still not efficiently target 
LSCs.91 This indicates that having 
low levels of the signaling molecule 
ROS is not the main mechanism that 
drives chemoresistance in LSCs. Thus, 
the detailed molecular consequences 
of low mitochondrial content and 
chemotherapy resistance are still not 
known.
Concluding remarks
High rates of disease relapse represent 
the current challenge of AML therapy. 
However, recent research is starting 
to shed light on the nature of the cells 
that drive AML relapse after initial 
reduction of leukemic blasts by various 
therapy strategies. LSCs likely survive 
conventional chemotherapy due to their 
unique metabolic characteristics and 
maintenance of their high expression 
of stemness-associated genes. 
Detailed analysis of the LSC biology 
is highly relevant to identify potential 
vulnerabilities of this cell population 
and to improve current treatment 
strategies. Based on data of this thesis 
and previous studies we learned that 
therapy-naïve leukemic cells with the 
lowest mitochondrial activity have the 
highest expression of stemness genes 
and the highest repopulation capacity. 
However, at the moment it is still 
not entirely clear how these features 
change during chemotherapy or disease 
relapse, and it would be interesting 
similar effects as a low mitochondrial 
content.85 Furthermore, the relatively 
high mitochondrial mass in HSCs 
observed in this study might result from 
altered dye in-/efflux properties of HSCs 
compared to other cell populations, or 
from different mitochondrial dynamics 
that influence the size and shape of 
mitochondria and thereby potentially 
the quantification of immunostainings. 
Mitochondria-depended differences 
could have a significant contribution to 
LSC characteristics such as increased 
chemotherapy resistance. A recent 
study performed with He-La cells 
demonstrated that the mitochondrial 
content correlates with the amount 
of pro-apoptotic proteins present in a 
cell, and that consequently cells with 
more mitochondria are more prone 
to die upon treatment with apoptosis 
inducing agents.86 Other studies in 
T-ALL cells observed that chemotherapy 
resistance induced by surrounding bone 
marrow mesenchymal stem cells (MSCs) 
coincides with transfer of mitochondria 
from T-ALL cells to MSCs,87 as well as 
with a lower ATP production in resistant 
cells.88 This is in line with the fact that 
programmed cell death in general is 
an energy demanding process,89 and 
is therefore potentially less likely 
induced in cells with low ATP levels. 
Moreover, decreased ATP production 
was associated with apoptosis resistance 
in breast cancer cells.90 Interestingly, 
Yu et al demonstrated that deletion of 
mitochondrial DNA in a breast cancer 
cell line resulted in increased expression 
of the drug efflux transporter ABCB1,90 
further highlighting a connection of 
low mitochondrial content and drug 
resistance as indicated in chapter 5 of 
this thesis. 
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sufficient for leukemic transformation, 
but that this protein might have 
important roles in interfering with p53-
mediated apoptosis and maintenance 
of preleukemic cells. Research that 
focuses on the fundamental molecular 
mechanisms of AML development and 
maintenance is essential to eventually 
improve AML patient survival. 
to address these questions in future 
studies. Furthermore, it is important 
to fully understand the process of AML 
evolution. Inference with alterations in 
preleukemic cells that promote increased 
self-renewal and stress resistance might 
prevent malignant transformation or 
disease relapse. In this thesis we learned 
that high expression of CITED2 is not 
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